• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2023

    6/27/23 5:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email

    Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023.

    Commenting on the fiscal year results (changes shown vs. fiscal 2022), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said:

    "Fiscal year 2023 was a challenging year as a result of a number of macroeconomic events and timing of sales. Consumers shifted their spend from goods to experiences and services. Lower sales in the bulk business were due in part to inventory adjustments after the global supply chain issues eased and lower sales in the e-commerce business were driven by a difference in strategy implemented by our third-party distributor."

    "Our manufacturing operations produced consistent and high-quality algae, however, the cost per kilo for spirulina in particular was a drag on the gross margin as we reduced production volume resulting in a higher cost per kilo to align with consumer demand."

    "In the fourth quarter of fiscal year 2023, the Company generated cash flow of $583,000 from operations as a result of the cash saving initiatives that we implemented in the second quarter, including slowing production and reducing headcount."

    "Despite the disappointing sales figures, I am hopeful for the future. We are well positioned to meet customer needs in the growing market for naturally derived high value nutritional products."

    Fiscal Year 2023

    Cyanotech reported net sales of $23,178,000 for fiscal 2023 compared to $35,968,000 in fiscal 2022, a decrease of 35.6%. Gross profit was $7,259,000, with gross profit margin of 31.3%, compared to gross profit of $13,566,000 and gross profit margin of 37.7%. Operating loss was $2,920,000 compared to operating income of $2,574,000.

    Net loss was $3,440,000 or $0.55 loss per share, compared to net income of $2,154,000 or $0.35 earnings per share.

    Fourth Quarter Fiscal 2023

    Cyanotech reported net sales of $5,391,000 for the fourth quarter of fiscal year 2023 compared to $8,126,000 in the fourth quarter of fiscal 2022, a decrease of 33.7%. Gross profit was $1,387,000 with gross profit margin of 25.7%, compared to gross profit of $2,894,000 and gross profit margin of 35.6% in the fourth quarter of fiscal 2022. Operating loss was $1,255,000 compared to operating income of $364,000 in the fourth quarter of fiscal 2022. Net loss was $1,430,000, or $0.23 loss per share, compared to net income of $277,000, or $0.04 earnings per share in the fourth quarter of fiscal 2022.

    Please review the Company's Form 10-K for the period ended March 31, 2023 for more detailed information.

    — Cyanotech will host a broadcast at 8:00 PM EDT on Wednesday, June 28, 2023, to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to [email protected] before 12 p.m. EDT on Wednesday, June 28, 2023. The Company will respond only to relevant questions relating to the Company's fourth quarter and fiscal 2023 financial performance and will not be accepting any questions or comments during the broadcast.

    To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.

    About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for more than 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all-natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company's mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech's BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity*. All Cyanotech products are produced from microalgae grown at our 96-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe ("GRAS") for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the Food and Drug Administration. Visit www.cyanotech.com for more information.

    *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

    "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, availability of financing, and our ability to continue as a going concern, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission.

    Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company's Form 10-K for the fiscal year ended March 31, 2023, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company's annual Form 10-K filings with the Securities and Exchange Commission.

     

    CYANOTECH CORPORATION

    CONSOLIDATED BALANCE SHEETS

     

     

     

     

     

     

    March 31,

     

    2023

    2022

     

    (in thousands, except share data)

    ASSETS

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash

    $

    974

     

    $

    2,589

     

    Accounts receivable, net of allowance for doubtful accounts of $64 in 2023 and $67 in 2022

     

    1,331

     

     

    3,664

     

    Inventories

     

    10,707

     

     

    9,466

     

    Prepaid expenses and other current assets

     

    484

     

     

    545

     

    Total current assets

     

    13,496

     

     

    16,264

     

    Equipment and leasehold improvements, net

     

    11,366

     

     

    11,885

     

    Operating lease right-of-use assets, net

     

    4,776

     

     

    3,787

     

    Other assets

     

    90

     

     

    109

     

    Total assets

    $

    29,728

     

    $

    32,045

     

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

    $

    1,021

     

    $

    2,362

     

    Accrued expenses

     

    1,101

     

     

    1,412

     

    Customer deposits

     

    89

     

     

    164

     

    Operating lease obligations, current portion

     

    483

     

     

    393

     

    Line of credit

     

    1,540

     

     

    —

     

    Line of credit – related party

     

    500

     

     

    —

     

    Current maturities of long-term debt

     

    3,469

     

     

    490

     

    Total current liabilities

     

    8,103

     

     

    4,821

     

     

     

     

     

     

     

     

    Long-term debt, less current maturities

     

    1,000

     

     

    4,336

     

    Long-term operating lease obligations

     

    4,275

     

     

    3,386

     

    Other long-term liabilities

     

    3

     

     

    15

     

    Total liabilities

     

    13,381

     

     

    12,558

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

    Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding

     

    —

     

     

    —

     

    Common stock of $0.02 par value, authorized 50,000,000 shares; issued and outstanding 6,271,971 shares at March 31, 2023 and 6,202,223 shares at March 31, 2022

     

    125

     

     

    124

     

    Additional paid-in capital

     

    33,856

     

     

    33,557

     

    Accumulated deficit

     

    (17,634

    )

     

    (14,194

    )

    Total stockholders' equity

     

    16,347

     

     

    19,487

     

    Total liabilities and stockholders' equity

    $

    29,728

     

    $

    32,045

     

     

    CYANOTECH CORPORATION

    CONSOLIDATED STATEMENTS OF OPERATIONS

     

     

     

     

     

     

     

     

    Years ended March 31,

     

    2023

    2022

    2021

     

    (in thousands, except per share data)

     

     

     

     

     

     

     

     

     

     

    Net sales

    $

    23,178

     

    $

    35,968

     

    $

    32,345

     

    Cost of sales

     

    15,919

     

     

    22,402

     

     

    21,228

     

    Gross profit

     

    7,259

     

     

    13,566

     

     

    11,117

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    General and administrative

     

    4,659

     

     

    5,367

     

     

    4,876

     

    Sales and marketing

     

    4,750

     

     

    4,913

     

     

    5,518

     

    Research and development

     

    770

     

     

    712

     

     

    639

     

    Total operating expense

     

    10,179

     

     

    10,992

     

     

    11,033

     

    (Loss) income from operations

     

    (2,920

    )

     

    2,574

     

     

    84

    Other income (expense):

     

     

     

     

     

     

     

     

     

    Interest expense, net

     

    (502

    )

     

    (392

    )

     

    (550

    )

    Gain on extinguishment of debt

     

    —

     

     

    —

     

     

    1,389

     

    Total other income (expense), net

     

    (502

    )

     

    (392

    )

     

    839

    (Loss) income before income taxes

     

    (3,422

    )

     

    2,182

     

     

    923

     

    Income tax expense

     

    (18

    )

     

    (28

    )

     

    (3

    )

    Net (loss) income

    $

    (3,440

    )

    $

    2,154

     

    $

    920

     

    Net (loss) income per share:

     

     

     

     

     

     

     

     

     

    Basic

    $

    (0.55

    )

    $

    0.35

     

    $

    0.15

    Diluted

    $

    (0.55

    )

    $

    0.35

     

    $

    0.15

    Shares used in calculation of net (loss) income per share:

     

     

     

     

     

     

     

     

     

    Basic

     

    6,244

     

     

    6,157

     

     

    6,070

     

    Diluted

     

    6,244

     

     

    6,168

     

     

    6,079

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230620870993/en/

    Get the next $CYAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/16/25 3:40:05 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Miyashiro Jennifer A.S.

    3 - CYANOTECH CORP (0000768408) (Issuer)

    9/12/25 3:24:28 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/2/25 6:19:32 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CYAN
    SEC Filings

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 15-12G filed by Cyanotech Corporation

    15-12G - CYANOTECH CORP (0000768408) (Filer)

    2/13/26 2:42:59 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation

    SC 13E3/A - CYANOTECH CORP (0000768408) (Subject)

    2/13/26 2:09:31 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation

    SC 13E3/A - CYANOTECH CORP (0000768408) (Subject)

    2/3/26 5:18:38 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/3/24 3:27:06 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    10/1/24 4:42:34 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

    4 - CYANOTECH CORP (0000768408) (Issuer)

    9/27/24 1:33:41 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Leadership Updates

    Live Leadership Updates

    View All

    Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

    Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

    8/1/23 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    10/3/24 6:39:03 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/12/24 12:25:52 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

    SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

    9/6/24 12:45:58 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $CYAN
    Financials

    Live finance-specific insights

    View All

    Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter of fiscal year 2026, ended September 30, 2025. Commenting on the second quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Our second quarter reflected continued momentum in both sales growth and profitability. Total sales increased 19.3% year-over-year, driven by higher bulk sales and strong performance in our online channels. "We also saw meaningful improvement in gross margin as our production volumes continued to increase, driving lower per

    11/10/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026

    Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2026, ended June 30, 2025. Commenting on the first quarter of fiscal year 2026 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "While top-line revenue remained relatively flat compared to the prior year, I am encouraged by the meaningful improvement in both gross margin and net loss reduction. Our margin expansion, from 25.0% in the prior year to 30.5%, reflects the continuation of strong operational discipline and improved production efficiency." "We re

    8/6/25 8:00:00 AM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025

    Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2025, ended March 31, 2025. Commenting on the fiscal year results (changes shown vs. fiscal 2024), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal 2025 was a year of meaningful progress for Cyanotech. Revenue grew 5%, gross margin improved by nearly 3 points and we reduced our operating loss by almost 45%." "Looking ahead, we remain cautious. Economic uncertainty, shifting demand and potential new tariffs could impact costs and global markets. W

    6/20/25 12:00:00 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care